Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 44Lung Neoplasms 9Brain Neoplasms 7NSCLC 4Pancreatic Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Esophageal Neoplasms 2EGF-R Positive Non-Small Cell Lung Cancer 2Adenocarcinoma of Lung 2Adenocarcinoma 2Squamous Cell Carcinoma of Lung 1Plasma EGFR Mutation-positive Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non-small Cell Lung Cancer Metastatic 1Non-Small-Cell Lung 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms, Second Primary 1Neoplasm Metastasis 1Drug-Related Side Effects and Adverse Reactions 1Bronchial Neoplasms 1Breast Neoplasms 1

Interventions

Drug Therapy 3Temozolomide 2Radiotherapy 2Radiosurgery 2Leucovorin 2Irinotecan 2Fluorouracil 2sacubitril and valsartan sodium hydrate drug combination 1icotinib 1dostarlimab 1beta Carotene 1avelumab 1alpha-Tocopherol 1Varenicline 1Tyrosine Kinase Inhibitors 1Trastuzumab 1Tobacco Use Cessation Devices 1Therapeutics 1Thalidomide 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Semen Analysis 1Registries 1Probiotics 1Patient Reported Outcome Measures 1Panitumumab 1Nicotine Chewing Gum 1Myofascial Release Therapy 1Megestrol Acetate 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Second Primary × icotinib × Clear all
NCT02283424 2014-11-05

Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

Chinese PLA General Hospital

Phase 4 Unknown
10 enrolled
Tumor-Agnostic

Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡